LIQUIDIA CORPORATION - COMMON STOCK

Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement

11 Sep 2024 08:26:18 By Nasdaq GlobeNewswire

Liquidia to Present at Upcoming Investor Conferences

28 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD

22 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

19 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions

16 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update

07 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024

31 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)

18 Jun 2024 08:42:18 By Nasdaq GlobeNewswire

District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch

03 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference

29 May 2024 08:00:00 By Nasdaq GlobeNewswire

Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update

13 May 2024 17:43:14 By Nasdaq GlobeNewswire

Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD

10 May 2024 08:00:00 By Nasdaq GlobeNewswire

Liquidia Corporation to Present at BofA Securities Health Care Conference 2024

07 May 2024 08:30:00 By Nasdaq GlobeNewswire

Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024

07 May 2024 08:00:01 By Nasdaq GlobeNewswire

Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference

02 Apr 2024 09:00:10 By Nasdaq GlobeNewswire

Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder

01 Apr 2024 06:00:44 By Nasdaq GlobeNewswire

Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

13 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024

06 Mar 2024 06:30:41 By Nasdaq GlobeNewswire

Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress

30 Jan 2024 06:30:11 By Nasdaq GlobeNewswire

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder

25 Jan 2024 06:00:57 By Nasdaq GlobeNewswire